Benefits of randomized control trials in accelerated approvals for oncology therapeutics
In 1992 the US FDA established the accelerated approval pathway for drug development as treatment options for serious or life-threatening conditions like cancer based on the effect the drug has on surrogate measures or an intermediate clinical end-point that could predict the real endpoint. However, these investigational drugs are subjected to post-approval confirmatory studies which […]
Benefits of randomized control trials in accelerated approvals for oncology therapeutics Read More »